Cost-Per-Number Needed To Treat (Nnt) Analysis Of Infliximab Compared To Adalimumab In The Treatment Of Moderate To Severe Ulcerative Colitis In The Brazilian Public Health Care System (Sus)
Abstract
Authors
A.D. Morais M.L. Pereira